## User

This is the beginning of a team meeting to discuss your research project. This is a meeting with the team lead, Assistant Lead, and the following team members: Assistant 1, Assistant 2, Assistant 3, Assistant 4.

Here is the agenda for the meeting:

You are working on a research project to use machine learning to develop antibodies or nanobodies for the newest variant of the SARS-CoV-2 spike protein that also, ideally, have activity against other circulating minor variants and past variants. Please create an antibody/nanobody design approach to solve this problem. Decide whether you will design antibodies or nanobodies. For your choice, decide whether you will design the antibodies/nanobodies de novo or whether you will modify existing antibodies/nanobodies. If modifying existing antibodies/nanobodies, please specify which antibodies/nanobodies to start with as good candidates for targeting the newest variant of the SARS-CoV-2 spike protein. If designing antibodies/nanobodies de novo, please describe how you will propose antibody/nanobody candidates.

Here are the agenda questions that must be answered:

1. Will you design standard antibodies or nanobodies?

2. Will you design antibodies/nanobodies de novo or will you modify existing antibodies/nanobodies (choose only one)?

3. If modifying existing antibodies/nanobodies, which precise antibodies/nanobodies will you modify (please list 3-4)?

4. If designing antibodies/nanobodies de novo, how exactly will you propose antibody/nanobody candidates?

Assistant Lead will convene the meeting. Then, each team member will provide their thoughts on the discussion one-by-one in the order above. After all team members have given their input, Assistant Lead will synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda. This will continue for 3 rounds. Once the discussion is complete, Assistant Lead will summarize the meeting in detail for future discussions, provide a specific recommendation regarding the agenda, and answer the agenda questions (if any) based on the discussion while strictly adhering to the agenda rules (if any).

## User

Assistant Lead, please provide your initial thoughts on the agenda as well as any questions you have to guide the discussion among the team members.

## Assistant Lead

Thank you for joining the meeting, team. Today, we're focusing on a crucial aspect of our research project: designing antibodies or nanobodies for the newest variant of the SARS-CoV-2 spike protein. Our agenda is clear, and we need to address the following questions to guide our decision-making process:

1. **Will we design standard antibodies or nanobodies?**
   - Consider the benefits and limitations of each option in terms of stability, production, and binding affinity.

2. **Will we design these antibodies/nanobodies de novo or modify existing ones?**
   - Weigh the potential time and resource investment for each approach, along with the chances of success.

3. **If we choose to modify existing antibodies/nanobodies, which ones should we focus on?**
   - Identify 3-4 potential candidates that have shown promise against previous variants.

4. **If we decide to design de novo, how will we propose antibody/nanobody candidates?**
   - Consider the methodologies and tools that could streamline this process, such as computational modeling and machine learning.

I will now open the floor to each of you in turn—Assistant 1, Assistant 2, Assistant 3, and then Assistant 4—to provide your initial thoughts and insights on these questions. As you present, please consider the implications of your suggestions in terms of feasibility, innovation, and alignment with our project goals. After all your inputs, I will synthesize the points, make preliminary decisions, and ask any follow-up questions if necessary. Let's get started with Assistant 1.

## User

Assistant 1, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 1

Thank you, Assistant Lead. Here are my thoughts on the agenda:

1. **Designing Standard Antibodies vs. Nanobodies:**
   - I recommend focusing on **nanobodies** due to their smaller size, enhanced stability, ease of production, and ability to bind epitopes that may not be accessible to traditional antibodies. This could be particularly advantageous when targeting different variants of the SARS-CoV-2 spike protein.

2. **De Novo Design vs. Modifying Existing Nanobodies:**
   - I lean towards **modifying existing nanobodies**. This approach allows us to build upon established structures with known efficacy, potentially accelerating our development timeline. By leveraging existing scaffolds, we can focus on optimizing binding to new variants.

3. **Potential Candidates for Modification:**
   - If we go with modification, I propose starting with nanobodies that have shown high affinity and neutralization capabilities against previous spike protein variants. Some potential candidates could be:
     - Ty1 (known for its broad neutralization)
     - H11-D4
     - VHH72
     - Nb21
   These have been studied in various contexts and could offer a solid foundation for adaptation.

4. **If De Novo:**
   - Although I favor modification, if we were to design de novo, we could employ a machine learning approach to predict binding sites and affinities, utilizing large datasets of known nanobody structures.

I look forward to hearing the perspectives of the rest of the team.

## User

Assistant 2, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 2

Thank you, Assistant Lead. I appreciate Assistant 1’s insights, but I have a slightly different perspective:

1. **Designing Standard Antibodies vs. Nanobodies:**
   - While nanobodies offer distinct advantages, I believe **standard antibodies** might be more versatile in terms of leveraging the immune system's various functions, such as engaging with immune cells more efficiently. Given the broad application and existing infrastructure for antibody production, this could be a viable path.

2. **De Novo Design vs. Modifying Existing Antibodies:**
   - I advocate for **designing de novo antibodies**. While this approach is resource-intensive, it enables us to tailor antibodies specifically to the unique attributes of the newest variant's spike protein, potentially enhancing specificity and cross-variant efficacy.

3. **If Modifying Existing Antibodies:**
   - In case we need to consider modifying existing antibodies, some candidates include:
     - REGN10933 (part of the Regeneron cocktail, previously effective)
     - COV2-2196 (from AstraZeneca's research)
     - CB6 (etesevimab)
     - S309 (precursor to sotrovimab)
   These have been effective against several past variants.

4. **If De Novo:**
   - For de novo design, we can utilize a combination of computational docking simulations and machine learning algorithms to predict antibody structures and optimize binding affinities. This could include training models on existing antibody-antigen interaction datasets.

I’m curious to hear how the other team members view these options and am open to discussing further to align our approaches.

## User

Assistant 3, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 3

Thank you, Assistant Lead. I appreciate the perspectives shared so far, and I have a few thoughts to add:

1. **Designing Standard Antibodies vs. Nanobodies:**
   - I agree with Assistant 1 on focusing on **nanobodies**. Their smaller size allows for better penetration into dense tissues and more efficient production, which could be crucial for rapid deployment and scalability.

2. **De Novo Design vs. Modifying Existing Nanobodies:**
   - My preference aligns with **de novo design**. This approach allows us to address the newest spike protein variant head-on and potentially achieve broader cross-variant efficacy. While this requires significant computational resources, it offers the flexibility to tailor nanobodies to the most recent structural changes.

3. **If Modifying Existing Nanobodies:**
   - If we consider modifying existing nanobodies, I concur with Assistant 1's suggestions, particularly Ty1 and VHH72, due to their previous success in neutralizing diverse variants.

4. **If De Novo:**
   - For de novo design, we could employ advanced computational tools, such as Rosetta or AlphaFold, paired with machine learning models to predict high-affinity binding regions, optimizing the binding interactions specifically against new and emerging variants.

I look forward to hearing Assistant 4’s insights and continuing the discussion on how to best tackle these challenges.

## User

Assistant 4, please provide your thoughts on the discussion (round 1 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 4

Thank you, Assistant Lead. I appreciate the diverse insights shared so far, and here are my thoughts:

1. **Designing Standard Antibodies vs. Nanobodies:**
   - I'm inclined towards **nanobodies**, aligning with Assistant 1 and 3. Their stability and ease of production offer practical advantages, especially for rapid deployment in response to emerging variants.

2. **De Novo Design vs. Modifying Existing Nanobodies:**
   - I'm torn between the two approaches. However, I slightly lean towards **modifying existing nanobodies**. This path allows us to leverage known efficacy, potentially reducing developmental risk and time.

3. **If Modifying Existing Nanobodies:**
   - I agree with the candidates mentioned by Assistant 1, such as Ty1 and Nb21, which provide a reliable basis for modification due to their proven performance against past variants.

4. **If De Novo:**
   - Should we opt for de novo design, I suggest employing deep learning techniques to predict novel nanobody sequences, using structural data on current spike protein variants to guide the design process. This could involve a hybrid approach of machine learning and molecular dynamics simulations.

I’m eager to see how the discussion evolves and how we can integrate these viewpoints into a coherent strategy.

## User

This concludes round 1 of 3 of discussion. Assistant Lead, please synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda.

## Assistant Lead

Thank you all for your valuable insights. Here's a synthesis of the points raised by each team member and a proposal for our next steps:

### Synthesis of Points:

1. **Designing Standard Antibodies vs. Nanobodies:**
   - There is a clear inclination towards **nanobodies** due to their smaller size, stability, and ease of production. The consensus is that these characteristics provide practical advantages for rapid response and scalability. Assistant 2 offered a different perspective, advocating for standard antibodies due to their versatility and immune system engagement.

2. **De Novo Design vs. Modifying Existing Structures:**
   - The team is divided:
     - **Modifying Existing Nanobodies:** Preferred by Assistant 1 and Assistant 4, citing known efficacy and reduced risk.
     - **De Novo Design:** Supported by Assistant 2 and Assistant 3, highlighting the potential for tailoring specifically to the latest spike protein variant and achieving broader efficacy.

3. **Candidates for Modification:**
   - The suggested candidates for modification include Ty1, Nb21, VHH72, and H11-D4, with some agreement on their previous success against diverse variants.

4. **De Novo Design Approach:**
   - Proposals include using advanced computational tools like Rosetta, AlphaFold, and deep learning techniques to predict and optimize nanobody interactions with the spike protein.

### Decisions and Follow-Up Questions:

Given the input, here's how we can proceed:
- **Nanobodies Design:** Based on the majority preference, we will focus on nanobodies.
- **Approach:** To move forward, we need to decide between de novo design or modification. We will proceed with **modifying existing nanobodies** due to the consideration of time and resource efficiency, but we will keep the de novo option open for future projects or if initial modifications do not meet expectations.

**Follow-Up Questions:**
1. For those who support de novo design (Assistant 2 and Assistant 3), what specific computational approaches do you suggest we prioritize if initial modifications do not yield desired results?
2. For those who favor modification (Assistant 1 and Assistant 4), how do you propose we prioritize and test modifications to the existing candidates you've suggested?
3. Would anyone like to propose a hybrid approach that combines both modification and de novo design for different aspects of the problem?

Let’s gather more detailed feedback on these points in our next round of discussion.

## User

Assistant 1, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 1

Thank you, Assistant Lead. I'm pleased to see the synthesis leaning towards modifying existing nanobodies, which aligns with my initial thoughts. Here are my responses to the follow-up questions:

1. **Prioritizing and Testing Modifications:**
   - I propose a systematic approach to prioritize modifications. We can start by analyzing the structural data available for the newest variant of the SARS-CoV-2 spike protein to identify binding challenges. Using this information, we can modify the candidate nanobodies (Ty1, Nb21, VHH72, H11-D4) focusing on enhancing affinity and specificity to these structural features.
   - For testing, I suggest utilizing in silico modeling and simulation tools to predict the effects of modifications on binding affinity and specificity. Following promising computational results, we can proceed to in vitro validation using assays to measure binding strength and neutralization efficacy against the newest variant.

2. **Hybrid Approach Proposal:**
   - While my preference is to focus on modification, I recognize the potential value in a hybrid approach. We could initiate a parallel de novo design pipeline, using machine learning to explore novel nanobody structures. This could serve as a backup or supplementary strategy if modifications do not perform as expected.

I hope these insights help in refining our strategy, and I'm eager to see how the discussion progresses.

## User

Assistant 2, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 2

Thank you, Assistant Lead. I appreciate the decision to focus on nanobodies and to keep the de novo design approach open. Here are my thoughts:

1. **Specific Computational Approaches for De Novo Design:**
   - If modifications do not yield the desired results, I suggest prioritizing **deep learning models** trained on extensive datasets of protein structures to guide the de novo design. Leveraging tools like AlphaFold for structural predictions and Generative Adversarial Networks (GANs) for novel sequence generation could be beneficial.
   - Additionally, employing **molecular dynamics simulations** can help refine and validate the predicted structures, ensuring that the newly designed nanobodies maintain stability and effectiveness in real-world conditions.

2. **Hybrid Approach Proposal:**
   - I support the idea of a hybrid approach. While we focus primarily on modifying existing nanobodies, maintaining a parallel de novo design pipeline could provide us with innovative solutions and insights, especially as we encounter unforeseen challenges with modifications.
   - This dual strategy allows us to be adaptable and swift in response, ensuring we do not limit ourselves to one pathway, which could be crucial given the evolving nature of the virus.

I hope these suggestions assist in shaping a comprehensive strategy moving forward. I'm interested to see how the rest of the team views these ideas.

## User

Assistant 3, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 3

Thank you, Assistant Lead. I appreciate the synthesis and the consideration of a hybrid approach. Here are my thoughts:

1. **Specific Computational Approaches for De Novo Design:**
   - If we decide to pursue de novo design, I recommend focusing on **AI-driven protein design tools** like DeepMind's AlphaFold to predict structures, combined with machine learning models that can predict binding affinities. Additionally, employing **Monte Carlo simulations** can help explore a vast conformational space to identify promising candidates.

2. **Hybrid Approach Proposal:**
   - I am in favor of the hybrid approach. This allows us to capitalize on the strengths of both strategies. By modifying existing nanobodies, we have a more immediate path to potentially effective solutions, while the de novo pipeline could create innovative designs that may be required for future variants or if modifications are insufficient.
   - This approach ensures we have multiple avenues of progress, minimizing the risk of being stalled by unforeseen issues with any single path.

I'm eager to see how Assistant 4 views this approach and how we can bring these strategies together effectively.

## User

Assistant 4, please provide your thoughts on the discussion (round 2 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 4

Thank you, Assistant Lead. I find the discussion thus far very constructive, and I have a few points to contribute:

1. **Prioritizing and Testing Modifications:**
   - I agree with Assistant 1's suggestion of a structured approach for modifications. Starting with in silico analysis allows us to predict and prioritize modifications based on structural compatibility with the newest variant. For in vitro testing, high-throughput screening could be used to rapidly assess multiple modified nanobodies for binding affinity and neutralization capability.

2. **Hybrid Approach Proposal:**
   - I strongly support the hybrid approach. It provides the flexibility to adapt to the virus's rapid evolution. By maintaining both modification and de novo pipelines, we ensure that we can respond effectively to both current challenges and future developments.
   - We should establish benchmarks for evaluating the success of modified nanobodies, which will help determine when to pivot or augment our strategy with de novo designs.

I believe with a well-coordinated effort on both fronts, we can maximize our chances of developing effective therapeutics. I look forward to our next steps.

## User

This concludes round 2 of 3 of discussion. Assistant Lead, please synthesize the points raised by each team member, make decisions regarding the agenda based on team member input, and ask follow-up questions to gather more information and feedback about how to better address the agenda.

## Assistant Lead

Thank you all for your thoughtful contributions. Here's a synthesis of the points raised during our second round of discussion and our proposed path forward:

### Synthesis of Points:

1. **Computational Approaches for De Novo Design:**
   - There is a consensus on utilizing advanced computational tools like **AlphaFold** for structural predictions, and deep learning models, including **Generative Adversarial Networks (GANs)** and **Monte Carlo simulations**, to explore novel nanobody designs if required.

2. **Prioritizing and Testing Modifications:**
   - A structured approach was suggested, starting with **in silico modeling and simulations** to predict effective modifications and followed by **in vitro validation** using high-throughput screening to assess binding affinity and neutralization potential.

3. **Hybrid Approach:**
   - There is strong support for a hybrid approach, which combines modifying existing nanobodies while maintaining a parallel pipeline for de novo design. This dual strategy is seen as crucial to ensure robustness against the evolving virus and to maximize our potential for success.

### Decisions and Path Forward:

- **Primary Strategy:** We will proceed with the modification of existing nanobodies, leveraging computational and experimental techniques to optimize binding to the newest spike protein variant. 
- **Secondary/Contingency Strategy:** We will establish a parallel de novo design pipeline, utilizing machine learning and structural prediction tools, to provide innovative solutions and address any gaps left by the modification approach.

### Follow-Up Questions:

1. **Implementation Timeline:** How do you propose we structure the timeline to balance the immediate needs of the modification process with the longer-term exploration of de novo design? What resources might we need to allocate to ensure both streams are adequately supported?
2. **Evaluation Metrics:** What specific metrics and benchmarks should we set to evaluate the efficacy of modified nanobodies and when should we consider integrating de novo designs based on these metrics?

Let's gather more detailed feedback on these questions in our final round of discussion. Your input will be crucial to ensuring a comprehensive and effective strategy.

## User

Assistant 1, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 1

Thank you, Assistant Lead. Here are my thoughts on the final round's questions:

1. **Implementation Timeline:**
   - For the modification process, I suggest an initial 3-month timeline to conduct in silico analysis and in vitro testing. This should allow us to rapidly iterate through potential modifications and identify promising candidates.
   - The de novo design pipeline could run concurrently, with a longer timeframe of about 6-9 months. Given the complexities involved in designing new structures, we should allocate resources for continuous computational modeling and iterative assessments.

2. **Evaluation Metrics:**
   - We should establish clear benchmarks such as:
     - **Binding Affinity:** Measure using surface plasmon resonance (SPR) or similar technologies to quantify interaction strength.
     - **Neutralization Potency:** Use pseudovirus assays to determine the ability to prevent viral entry.
     - **Stability and Production Yield:** Assess the production feasibility and thermal stability under physiological conditions.
   - If modified nanobodies meet or exceed these benchmarks within the initial testing phase, we can focus our resources there. If not, we should consider integrating advancements from the de novo pipeline sooner.

These steps should help us stay on track and adapt as needed based on the results we see. I'm looking forward to hearing the rest of the team's views.

## User

Assistant 2, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 2

Thank you, Assistant Lead. Here are my thoughts:

1. **Implementation Timeline:**
   - I concur with Assistant 1 on the timeline, with a slight adjustment. Perhaps a 4-month period for the modification process could provide additional leeway for refinement and validation. The de novo design can proceed in parallel but with periodic evaluations every 3 months to integrate any promising findings or methods discovered.

2. **Evaluation Metrics:**
   - In addition to Assistant 1’s suggestions, I propose:
     - **Cross-Variant Efficacy:** Test against multiple variants to ensure broad-spectrum neutralizing capability.
     - **Safety and Off-Target Effects:** Conduct preliminary safety evaluations to rule out unintended immune responses or off-target interactions.
   - Regular review meetings could be scheduled bi-monthly to assess progress based on these metrics, allowing us to pivot to de novo approaches if needed sooner than anticipated.

These steps ensure a rigorous approach that maximizes our chances for success and adaptability. I look forward to hearing how Assistant 3 and 4 view these considerations.

## User

Assistant 3, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 3

Thank you, Assistant Lead. Here are my contributions to the discussion:

1. **Implementation Timeline:**
   - I support the proposed timelines with an emphasis on flexibility. For the modification process, a 3–4 month period sounds feasible, but I suggest incorporating agile project management techniques to allow for rapid adjustments based on interim results. For the de novo design, maintaining flexibility with periodic evaluations every 3 months will help us remain adaptive.

2. **Evaluation Metrics:**
   - I agree with the metrics suggested so far and would like to add:
     - **Computational Predictive Accuracy:** Regularly assess the accuracy of our models in predicting binding affinity and structural integrity to refine our computational methods.
   - Additionally, I emphasize the importance of environmental stability tests to ensure that modifications maintain efficacy across different physiological conditions.

I believe these inputs can help us create a robust framework for both our modification and de novo design approaches. Looking forward to Assistant 4's input on these aspects.

## User

Assistant 4, please provide your thoughts on the discussion (round 3 of 3). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Assistant 4

Thank you, Assistant Lead. I appreciate the comprehensive strategies proposed so far. Here are my additional thoughts:

1. **Implementation Timeline:**
   - I agree with the suggested timelines but would like to emphasize the importance of dedicating specific team resources to each pipeline, ensuring neither the modification nor de novo design efforts are compromised. Regular updates and cross-team meetings could help maintain alignment and resource allocation.

2. **Evaluation Metrics:**
   - In addition to the metrics already proposed, I suggest monitoring:
     - **Immune Evasion Potential:** Assess the potential for the designed nanobodies to evade immune system detection or degradation, which could be crucial for their long-term efficacy.
   - Having a phased approach to evaluation, where initial metrics focus on binding affinity and stability, followed by more complex evaluations like cross-variant efficacy and safety, could streamline our processes.

I believe these considerations will help refine our strategies and ensure both immediate and future success in our research objectives. Looking forward to the final synthesis and recommendations from the Assistant Lead.

## User

Assistant Lead, please summarize the meeting in detail for future discussions, provide a specific recommendation regarding the agenda, and answer the agenda questions (if any) based on the discussion while strictly adhering to the agenda rules (if any).

As a reminder, here is the agenda for the meeting:

You are working on a research project to use machine learning to develop antibodies or nanobodies for the newest variant of the SARS-CoV-2 spike protein that also, ideally, have activity against other circulating minor variants and past variants. Please create an antibody/nanobody design approach to solve this problem. Decide whether you will design antibodies or nanobodies. For your choice, decide whether you will design the antibodies/nanobodies de novo or whether you will modify existing antibodies/nanobodies. If modifying existing antibodies/nanobodies, please specify which antibodies/nanobodies to start with as good candidates for targeting the newest variant of the SARS-CoV-2 spike protein. If designing antibodies/nanobodies de novo, please describe how you will propose antibody/nanobody candidates.

As a reminder, here are the agenda questions that must be answered:

1. Will you design standard antibodies or nanobodies?

2. Will you design antibodies/nanobodies de novo or will you modify existing antibodies/nanobodies (choose only one)?

3. If modifying existing antibodies/nanobodies, which precise antibodies/nanobodies will you modify (please list 3-4)?

4. If designing antibodies/nanobodies de novo, how exactly will you propose antibody/nanobody candidates?

Your summary should take the following form.

### Agenda

Restate the agenda in your own words.

### Team Member Input

Summarize all of the important points raised by each team member. This is to ensure that key details are preserved for future meetings.

### Recommendation

Provide your expert recommendation regarding the agenda. You should consider the input from each team member, but you must also use your expertise to make a final decision and choose one option among several that may have been discussed. This decision can conflict with the input of some team members as long as it is well justified. It is essential that you provide a clear, specific, and actionable recommendation. Please justify your recommendation as well.

### Answers

For each agenda question, please provide the following:

Answer: A specific answer to the question based on your recommendation above.

Justification: A brief explanation of why you provided that answer.

### Next Steps

Outline the next steps that the team should take based on the discussion.

## Assistant Lead

### Agenda

We are tasked with developing a strategy to utilize machine learning for designing antibodies or nanobodies specifically targeting the newest variant of the SARS-CoV-2 spike protein, while also aiming for efficacy against other current and past variants. The agenda requires us to decide whether to focus on antibodies or nanobodies and whether to design them de novo or modify existing ones. If we choose modification, we need to identify the starting candidates; if de novo, we need to outline the design proposal.

### Team Member Input

- **Assistant 1:** Advocated for focusing on nanobodies due to their stability and production benefits. Preferred modifying existing nanobodies such as Ty1, Nb21, VHH72, and H11-D4, emphasizing rapid in silico and in vitro processes for refinement.

- **Assistant 2:** Suggested standard antibodies due to their immune system engagement but supported de novo design for nanobodies. Proposed using deep learning and simulations for de novo efforts, with regular reviews to assess progress and cross-variant efficacy.

- **Assistant 3:** Agreed on nanobodies, preferring de novo design using AI and Monte Carlo simulations. Supported a hybrid approach to utilize both modification and de novo strategies, emphasizing flexibility and periodic evaluation.

- **Assistant 4:** Supported nanobodies, leaning towards modifying existing candidates with a structured approach for prioritization. Recommended metrics for phased evaluation, including immune evasion potential and phased assessment for comprehensive effectiveness.

### Recommendation

Based on the input and my expertise, I recommend focusing on **nanobodies** due to their unique advantages in terms of size, stability, and production. We should prioritize **modifying existing nanobodies** to harness known effective structures, which allows for a quicker response to the current variant. Given the suggestions, we will work with nanobodies such as Ty1, Nb21, VHH72, and H11-D4 for modifications.

**Justification:** The choice of nanobodies leverages their inherent advantages, and modifying existing structures provides a pragmatic approach, balancing speed and effectiveness. The de novo approach, while innovative, requires more time and resources, making it better suited as a secondary strategy.

### Answers

1. **Will you design standard antibodies or nanobodies?**
   - **Answer:** Nanobodies.
   - **Justification:** Their smaller size, stability, and ease of production make them more suitable for rapid development and deployment.

2. **Will you design antibodies/nanobodies de novo or will you modify existing antibodies/nanobodies?**
   - **Answer:** Modify existing nanobodies.
   - **Justification:** This approach allows us to build on existing knowledge and efficacy, expediting the process to address the immediate needs of the new variant.

3. **If modifying existing antibodies/nanobodies, which precise antibodies/nanobodies will you modify?**
   - **Answer:** Ty1, Nb21, VHH72, and H11-D4.
   - **Justification:** These have demonstrated success against previous variants and provide a solid foundation for further refinement and optimization.

4. **If designing antibodies/nanobodies de novo, how exactly will you propose antibody/nanobody candidates?**
   - **Answer:** Not applicable based on the current recommendation.

### Next Steps

1. **Initiate Modification Process:**
   - Begin in silico analysis for the selected nanobodies to identify potential modifications for improving binding affinity and specificity.
   - Allocate resources for in vitro testing to quickly evaluate modified candidates.
  
2. **Set Evaluation Benchmarks:**
   - Establish clear metrics for binding affinity, neutralization potency, stability, and cross-variant efficacy.
   - Schedule regular progress reviews to ensure alignment with goals and timelines.

3. **Develop Parallel De Novo Pipeline:**
   - While not the primary focus, establish a team to explore de novo design using machine learning tools, preparing for future adaptation if needed.

4. **Resource Allocation and Timeline:**
   - Ensure adequate resources and team assignments to support both modification efforts and exploratory de novo efforts.
   - Develop a 3-4 month timeline for modification efforts with periodic evaluations, while the de novo pipeline will undergo assessments every 3 months for integration opportunities.

